邵荣光. 基于单克隆抗体的肿瘤免疫治疗J. 药学学报, 2020,55(6): 1110-1118. doi: 10.16438/j.0513-4870.2020-0135
引用本文: 邵荣光. 基于单克隆抗体的肿瘤免疫治疗J. 药学学报, 2020,55(6): 1110-1118. doi: 10.16438/j.0513-4870.2020-0135
SHAO Rong-guang. Monoclonal antibody-based cancer immunotherapyJ. Acta Pharmaceutica Sinica, 2020,55(6): 1110-1118. doi: 10.16438/j.0513-4870.2020-0135
Citation: SHAO Rong-guang. Monoclonal antibody-based cancer immunotherapyJ. Acta Pharmaceutica Sinica, 2020,55(6): 1110-1118. doi: 10.16438/j.0513-4870.2020-0135

基于单克隆抗体的肿瘤免疫治疗

Monoclonal antibody-based cancer immunotherapy

  • 摘要: 近年来,肿瘤免疫治疗已成为肿瘤免疫学基础和应用研究的一个重要领域。肿瘤免疫治疗主要有癌症疫苗、溶瘤病毒治疗、嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T cells)、免疫检查点阻滞和单克隆抗体等策略。其中,基于单克隆抗体的肿瘤免疫治疗发展最快。在过去20多年中,单克隆抗体已成为针对人类恶性肿瘤疗效显著且类型新颖的药物之一,特别是靶向免疫检查点的单克隆抗体药物在肿瘤免疫治疗中发挥重要作用。本文将综述基于单克隆抗体的肿瘤免疫治疗的现状、潜在的免疫调节机制、抗体作用靶分子和免疫治疗剂,探讨抗体类免疫治疗药物的发展趋势。

     

    Abstract: In recent years, cancer immunotherapy has become an important field of basic and applied researches of cancer immunology. Cancer immunotherapy mainly includes cancer vaccine, oncolytic virus therapy, chimeric antigen receptor T cells (CAR-T cells), immune checkpoint blocks, monoclonal antibodies, and other strategies. Among them, monoclonal antibody-based cancer immunotherapy has the fastest development. In the past 20 years, monoclonal antibody has become one of the drugs with remarkable curative effect and novel type for human malignant tumors, especially the monoclonal antibody targeting immune checkpoints, play an important role in immunotherapy. In this review, we will summarize the current situation of monoclonal antibody-based cancer immunotherapy, potential immune modulatory mechanism, antibody targeting molecules and its immunotherapeutic agents, and explore the trend of monoclonal antibody-based agents in cancer immunotherapy.

     

/

返回文章
返回